{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T07:40:47Z","timestamp":1762674047625},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,7,28]],"date-time":"2015-07-28T00:00:00Z","timestamp":1438041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,7,28]],"date-time":"2015-07-28T00:00:00Z","timestamp":1438041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Osteoprotegerin (OPG) is a key regulator of bone remodeling. Mutations in OPG are involved in a variety of human diseases. We have shown that cochlear spiral ganglion cells secrete OPG at high levels and lack of OPG causes sensorineural hearing loss in addition to the previously described conductive hearing loss. In order to study the regulation of OPG expression, we conducted a database search on regulatory elements in the promoter region of the <jats:italic>OPG<\/jats:italic> gene and identified two potential GATA-3 binding sites. Using luciferase assays and site directed mutagenesis, we demonstrate that these two elements are GATA-3 responsive and support GATA-3 transactivation in human HEK and HeLa cells. The expression of wild type GATA-3 activated OPG mRNA and protein expression, while the expression of a dominant negative mutant of GATA-3 or a <jats:italic>GATA-3<\/jats:italic> shRNA construct reduced <jats:italic>OPG<\/jats:italic> mRNA and protein levels. <jats:italic>GATA-3<\/jats:italic> deficient cells generated by expressing a <jats:italic>GATA-3<\/jats:italic> shRNA construct were sensitive to apoptosis induced by etoposide and TNF-\u03b1. This apoptotic effect could be partly prevented by the co-treatment with exogenous OPG. Our results suggest new approaches to rescue diseases due to GATA-3 deficiency \u2013 such as in <jats:bold>h<\/jats:bold>ypoparathyroidism, sensorineural <jats:bold>d<\/jats:bold>eafness and <jats:bold>r<\/jats:bold>enal (HDR) syndrome \u2013 by OPG therapy.<\/jats:p>","DOI":"10.1038\/srep12479","type":"journal-article","created":{"date-parts":[[2015,7,28]],"date-time":"2015-07-28T09:34:39Z","timestamp":1438076079000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Transactivation of human osteoprotegerin promoter by GATA-3"],"prefix":"10.1038","volume":"5","author":[{"given":"Shyan-Yuan","family":"Kao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantina M.","family":"Stankovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,7,28]]},"reference":[{"key":"BFsrep12479_CR1","doi-asserted-by":"publisher","first-page":"5050","DOI":"10.1210\/endo.142.12.8536","volume":"142","author":"S Khosla","year":"2001","unstructured":"Khosla, S. Minireview: the OPG\/RANKL\/RANK system. Endocrinology 142, 5050\u20135055 (2001).","journal-title":"Endocrinology"},{"key":"BFsrep12479_CR2","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","volume":"89","author":"WS Simonet","year":"1997","unstructured":"Simonet, W. S. et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309\u2013319 (1997).","journal-title":"Cell"},{"key":"BFsrep12479_CR3","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1210\/endo.139.3.5837","volume":"139","author":"H Yasuda","year":"1998","unstructured":"Yasuda, H. et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG\/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139, 1329\u20131337 (1998).","journal-title":"Endocrinology"},{"key":"BFsrep12479_CR4","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","volume":"12","author":"N Bucay","year":"1998","unstructured":"Bucay, N. et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12, 1260\u20131268 (1998).","journal-title":"Genes Dev."},{"key":"BFsrep12479_CR5","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1006\/bbrc.1998.8697","volume":"247","author":"A Mizuno","year":"1998","unstructured":"Mizuno, A. et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor\/osteoprotegerin. Biochem Biophys Res Commun. 247, 610\u2013615 (1998).","journal-title":"Biochem Biophys Res Commun."},{"key":"BFsrep12479_CR6","first-page":"1619","volume":"62","author":"I Holen","year":"2002","unstructured":"Holen, I., Croucher, P. I., Hamdy, F. C. & Eaton, C. L. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res. 62, 1619\u20131623 (2002).","journal-title":"Cancer Res."},{"key":"BFsrep12479_CR7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1023\/B:BREA.0000036900.48763.b3","volume":"86","author":"HL Neville-Webbe","year":"2004","unstructured":"Neville-Webbe, H. L. et al. Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat. 86, 269\u2013279 (2004).","journal-title":"Breast Cancer Res Treat."},{"key":"BFsrep12479_CR8","first-page":"912","volume":"63","author":"CM Shipman","year":"2003","unstructured":"Shipman, C. M. & Croucher, P. I. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand\/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. 63, 912\u2013916 (2003).","journal-title":"Cancer Res."},{"key":"BFsrep12479_CR9","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1002\/ijc.21606","volume":"118","author":"SS Cross","year":"2006","unstructured":"Cross, S. S. et al. Osteoprotegerin (OPG)\u2013a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int J Cancer. 118, 1901\u20131908 (2006).","journal-title":"Int J Cancer."},{"key":"BFsrep12479_CR10","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S0090-4295(00)01122-5","volume":"57","author":"JM Brown","year":"2001","unstructured":"Brown, J. M. et al. Osteoprotegerin and rank ligand expression in prostate cancer. Urology. 57, 611\u2013616 (2001).","journal-title":"Urology."},{"key":"BFsrep12479_CR11","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1002\/cncr.20550","volume":"101","author":"Y Mizutani","year":"2004","unstructured":"Mizutani, Y. et al. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma. Cancer. 101, 1794\u20131802 (2004).","journal-title":"Cancer."},{"key":"BFsrep12479_CR12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s00223-005-0237-y","volume":"78","author":"C Valero","year":"2006","unstructured":"Valero, C. et al. Osteoprotegerin and bone mass in squamous cell head and neck cancer patients. Calcif Tissue Int. 78, 343\u2013347 (2006).","journal-title":"Calcif Tissue Int."},{"key":"BFsrep12479_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.nbd.2013.04.008","volume":"56","author":"S-Y Kao","year":"2013","unstructured":"Kao, S.-Y. et al. Loss of osteoprotegerin expression in the inner ear causes degeneration of the cochlear nerve and sensorineural hearing loss. Neurobiol Dis. 56, 25\u201333 (2013).","journal-title":"Neurobiol Dis."},{"key":"BFsrep12479_CR14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/01.mlg.0000191466.09210.9a","volume":"116","author":"AF Zehnder","year":"2006","unstructured":"Zehnder, A. F. et al. Osteoprotegrin knockout mice demonstrate abnormal remodeling of the otic capsule and progressive hearing loss. Laryngoscope. 116, 201\u2013206 (2006).","journal-title":"Laryngoscope."},{"key":"BFsrep12479_CR15","doi-asserted-by":"publisher","first-page":"10119","DOI":"10.1074\/jbc.M006918200","volume":"276","author":"M Wan","year":"2001","unstructured":"Wan, M., Shi, X., Feng, X. & Cao, X. Transcriptional mechanisms of bone morphogenetic protein-induced osteoprotegrin gene expression. J Biol Chem. 276, 10119\u201310125 (2001).","journal-title":"J Biol Chem."},{"key":"BFsrep12479_CR16","doi-asserted-by":"publisher","first-page":"36241","DOI":"10.1074\/jbc.M104319200","volume":"276","author":"K Thirunavukkarasu","year":"2001","unstructured":"Thirunavukkarasu, K. et al. Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. J Biol Chem. 276, 36241\u201336250 (2001).","journal-title":"J Biol Chem."},{"key":"BFsrep12479_CR17","doi-asserted-by":"publisher","first-page":"4713","DOI":"10.1158\/1078-0432.CCR-07-5019","volume":"14","author":"EN De Toni","year":"2008","unstructured":"De Toni, E. N. et al. OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer. Clin Cancer Res. 14, 4713\u20134718 (2008).","journal-title":"Clin Cancer Res."},{"key":"BFsrep12479_CR18","first-page":"99","volume":"23","author":"MJ Weiss","year":"1995","unstructured":"Weiss, M. J. & Orkin, S. H. GATA-3 transcription factors: key regulators of hematopoiesis. Exp. Hematol. 23, 99\u2013107 (1995).","journal-title":"Exp. Hematol."},{"key":"BFsrep12479_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1006\/geno.1994.1217","volume":"21","author":"MC Labastie","year":"1994","unstructured":"Labastie, M. C. et al. (1994) Structure and expression of the human GATA-3 gene. Genomics 21, 1\u20136 (1994).","journal-title":"Genomics"},{"key":"BFsrep12479_CR20","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJM199210083271506","volume":"327","author":"RW Bilous","year":"1992","unstructured":"Bilous, R. W. et al. (1992) Brief report: autosomal dominant familial hypoparathyroidism, sensorineural deafness and renal dysplasia. N Engl J Med. 327, 1069\u20131074 (1992).","journal-title":"N Engl J Med."},{"key":"BFsrep12479_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1136\/jmg.37.1.33","volume":"37","author":"P Lichtner","year":"2000","unstructured":"Lichtner, P. et al. (2000) An HDR (hypoparathyroidism, deafness, renal dysplasia) syndrome locus maps distal to the DiGeorge syndrome region on 10p13\/14. J Med Genet. 37, 33\u201337 (2000).","journal-title":"J Med Genet."},{"key":"BFsrep12479_CR22","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/35019088","volume":"406","author":"H van Esch","year":"2000","unstructured":"van Esch, H. et al. GATA-3 haplo-insufficiency causes human HDR syndrome. Nature 406, 419\u2013422 (2000).","journal-title":"Nature"},{"key":"BFsrep12479_CR23","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1136\/jmg.38.6.374","volume":"38","author":"K Muroya","year":"2001","unstructured":"Muroya, K. et al. GATA-3 abnormalities and the phenotypic spectrum of HDR syndrome. J Med Genet. 38, 374\u2013380 (2001).","journal-title":"J Med Genet."},{"key":"BFsrep12479_CR24","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/jbmr.121","volume":"25","author":"RM Chen","year":"2010","unstructured":"Chen, R. M., Lin, Y. L. & Chou, C. W. GATA-3 transduces survival signals in osteoblasts through upregulation of bcl-x(L) gene expression. J Bone Miner Res. 25, 2193\u20132204 (2010).","journal-title":"J Bone Miner Res."},{"key":"BFsrep12479_CR25","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/art.24329","volume":"60","author":"JP van Hamburg","year":"2009","unstructured":"van Hamburg, J. P. et al. GATA-3 protects against severe joint inflammation and bone erosion and reduces differentiation of Th17 cells during experimental arthritis. Arthritis Rheum. 60, 750\u2013759 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFsrep12479_CR26","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1007\/PL00000940","volume":"58","author":"H Van Esch","year":"2001","unstructured":"Van Esch, H., & Devriendt, K. Transcription factor GATA-3 and human HDR syndrome. Cell. Mol. Life Sci. 58, 1296\u20131300 (2001).","journal-title":"Cell. Mol. Life Sci."},{"key":"BFsrep12479_CR27","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/jcp.21943","volume":"222","author":"J Chou","year":"2010","unstructured":"Chou, J., Provot, S. & Werd, Z. (2010) GATA-3 in development and cancer differentiation: cells GATA have it. J. Cell Physiol. 222, 42\u201349 (2010).","journal-title":"J. Cell Physiol."},{"key":"BFsrep12479_CR28","doi-asserted-by":"publisher","first-page":"4775","DOI":"10.1242\/dev.01370","volume":"131","author":"K Tsarovina","year":"2004","unstructured":"Tsarovina, K. et al. Essential role of Gata transcription factors in sympathetic neuron development. Development 131, 4775\u20134786 (2004).","journal-title":"Development"},{"key":"BFsrep12479_CR29","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1126\/science.290.5489.134","volume":"290","author":"Q Tong","year":"2000","unstructured":"Tong, Q. et al. Function of GATA transcription factors in preadipocyte-adipocyte transition. Science 290, 134\u2013138 (2000).","journal-title":"Science"},{"key":"BFsrep12479_CR30","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1084\/jem.184.3.1137","volume":"184","author":"N Hattori","year":"1996","unstructured":"Hattori, N., Kawamoto, H., Fujimoto, S., Kuno, K. & Katsura, Y. Involvement of transcription factors TCF-1 and GATA-3 in the initiation of the earliest step of T cell development in the thymus. J Exp Med. 184, 1137\u20131147 (1996).","journal-title":"J Exp Med."},{"key":"BFsrep12479_CR31","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1101\/gad.1115203","volume":"17","author":"CK Kaufman","year":"2003","unstructured":"Kaufman, C. K. et al. (2003) GATA-3: an unexpected regulator of cell lineage determination in skin. Genes Dev. 17, 2108\u20132122 (2003).","journal-title":"Genes Dev."},{"key":"BFsrep12479_CR32","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.cell.2006.09.048","volume":"127","author":"H Kouros-Mehr","year":"2006","unstructured":"Kouros-Mehr, H., Slorach, E. M., Sternlicht, M. D. & Werb, Z. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 127, 1041\u20131055 (2006).","journal-title":"Cell"},{"key":"BFsrep12479_CR33","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1002\/dvdy.22035","volume":"238","author":"A Maeda","year":"2009","unstructured":"Maeda, A. et al. Transcription factor GATA-3 is essential for lens development. Dev Dyn. 238, 2280\u20132291 (2009).","journal-title":"Dev Dyn."},{"key":"BFsrep12479_CR34","doi-asserted-by":"publisher","first-page":"715","DOI":"10.4049\/jimmunol.167.2.715","volume":"167","author":"MC Nawijn","year":"2001","unstructured":"Nawijn, M. C. et al. Enforced expression of GATA-3 during T cell development inhibits maturation of CD8 single-positive cells and induces thymic lymphoma in transgenic mice. J. Immunol. 167, 715\u2013723 (2001).","journal-title":"J. Immunol."},{"key":"BFsrep12479_CR35","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1369\/jhc.5A6626.2005","volume":"54","author":"A Gulbinas","year":"2006","unstructured":"Gulbinas, A. et al. Aberrant gata-3 expression in human pancreatic cancer. J Histochem Cytochem. 54, 161\u2013169 (2006).","journal-title":"J Histochem Cytochem."},{"key":"BFsrep12479_CR36","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ccr.2008.01.011","volume":"13","author":"H Kouros-Mehr","year":"2008","unstructured":"Kouros-Mehr, H. et al. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 13, 141\u2013152 (2008).","journal-title":"Cancer Cell"},{"key":"BFsrep12479_CR37","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1016\/j.humpath.2012.02.011","volume":"43","author":"H Miyamoto","year":"2012","unstructured":"Miyamoto, H. et al. GATA binding protein 3 is down-regulated in bladder cancer yet strong expression is an independent predictor of poor prognosis in invasive tumor. Hum Pathol. 43, 2033\u20132040 (2012).","journal-title":"Hum Pathol."},{"key":"BFsrep12479_CR38","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00109-010-0702-6","volume":"89","author":"M Ohta","year":"2011","unstructured":"Ohta, M. et al. Novel dominant-negative mutant of GATA-3 in HDR syndrome. J Mol Med (Berl). 89, 43\u201350 (2011).","journal-title":"J Mol Med (Berl)."},{"key":"BFsrep12479_CR39","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1423-0127-16-67","volume":"16","author":"S-Y Kao","year":"2009","unstructured":"Kao, S.-Y. (2009) DNA damage induces nuclear translocation of parkin. J Biomed Sci. 16, 67 (2009).","journal-title":"J Biomed Sci."},{"key":"BFsrep12479_CR40","doi-asserted-by":"publisher","first-page":"e7144","DOI":"10.1371\/journal.pone.0007144","volume":"23","author":"M Milo","year":"2009","unstructured":"Milo, M. et al. Genomic analysis of the function of the transcription factor gata3 during development of the mammalian inner ear. PLoS One. 23, e7144 (2009).","journal-title":"PLoS One."},{"key":"BFsrep12479_CR41","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.bbrc.2009.03.048","volume":"382","author":"S-Y Kao","year":"2009","unstructured":"Kao, S.-Y. Regulation of DNA repair by parkin. Biochem Biophys Res Commun. 382, 321\u2013325 (2009).","journal-title":"Biochem Biophys Res Commun."},{"key":"BFsrep12479_CR42","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1084\/jem.192.4.463","volume":"192","author":"H Min","year":"2000","unstructured":"Min, H. et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med. 192, 463\u2013474 (2000).","journal-title":"J Exp Med."},{"key":"BFsrep12479_CR43","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.mod.2003.12.006","volume":"121","author":"G Lawoko-Kerali","year":"2004","unstructured":"Lawoko-Kerali, G. et al. GATA-3 and NeuroD distinguish auditory and vestibular neurons during development of the mammalian inner ear. Mech. Dev. 121, 287\u2013299 (2004).","journal-title":"Mech. Dev."},{"key":"BFsrep12479_CR44","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.nbd.2004.02.004","volume":"16","author":"J van der Wees","year":"2004","unstructured":"van der Wees, J. et al. Hearing loss following Gata3 haploinsufficiency is caused by cochlear disorder. Neurobiol Dis. 16, 169\u2013178 (2004).","journal-title":"Neurobiol Dis."},{"key":"BFsrep12479_CR45","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.heares.2011.10.010","volume":"283","author":"M Haugas","year":"2012","unstructured":"Haugas, M., Lillevali, K. & Salminen, M. Defects in sensory organ morphogenesis and generation of cochlear hair cells in GATA-3-deficient mouse embryos. Hearing Res. 283, 151\u2013161 (2012).","journal-title":"Hearing Res."},{"key":"BFsrep12479_CR46","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.nbd.2005.05.025","volume":"20","author":"MA van Looij","year":"2005","unstructured":"van Looij, M. A. et al. GATA3 haploinsufficiency causes a rapid deterioration of distortion product otoacoustic emissions (DPOAEs) in mice. Neurobiol Dis. 20, 890\u2013897 (2005).","journal-title":"Neurobiol Dis."},{"key":"BFsrep12479_CR47","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1387\/ijdb.103178jd","volume":"55","author":"JS Duncan","year":"2011","unstructured":"Duncan, J. S., Lim. K.-C., Engel, J. D. & Fritzsch, B. Limited inner ear morphogenesis and neurosensory development are possible in the absence of GATA-3. Int. J. Dev. Biol. 55, 297\u2013303 (2011).","journal-title":"Int. J. Dev. Biol."},{"key":"BFsrep12479_CR48","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1093\/hmg\/ddt212","volume":"22","author":"XJ Luo","year":"2013","unstructured":"Luo, X. J. et al. GATA3 controls the specification of prosensory domain and neuronal survival in the mouse cochlea. Hum Mol Genet. 22, 3609\u20133623 (2013).","journal-title":"Hum Mol Genet."},{"key":"BFsrep12479_CR49","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.1523\/JNEUROSCI.4703-12.2013","volume":"33","author":"JM Appler","year":"2013","unstructured":"Appler, J. M. et al. GATA-3 is a critical regulator of cochlear wiring. J Neurosci. 33, 3679\u20133691 (2013).","journal-title":"J Neurosci."},{"key":"BFsrep12479_CR50","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1002\/dvdy.22149","volume":"238","author":"DM Alvarado","year":"2009","unstructured":"Alvarado, D. M., Veile, R., Speck, J., Warchol, M. & Lovett, M. Downstream targets of GATA3 in the vestibular sensory organs of the inner ear. Dev Dyn. 238, 3093\u20133102 (2009).","journal-title":"Dev Dyn."},{"key":"BFsrep12479_CR51","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.heares.2010.02.006","volume":"265","author":"KM Stankovic","year":"2010","unstructured":"Stankovic, K. M. et al. Differences in gene expression between the otic capsule and other bones. Hear Res. 265, 83\u201389 (2010).","journal-title":"Hear Res."},{"key":"BFsrep12479_CR52","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/01.mlg.0000150702.28451.35","volume":"115","author":"AF Zehnder","year":"2005","unstructured":"Zehnder, A. F., Kristiansen, A. G., Adams, J. C., Merchan, S. N. & McKenna, M. J. Osteoprotegerin in the inner ear may inhibit bone remodeling in the otic capsule. Laryngoscope 115, 172\u2013177 (2005).","journal-title":"Laryngoscope"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep12479","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep12479.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep12479.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T14:34:11Z","timestamp":1672929251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep12479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,28]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12,18]]}},"alternative-id":["BFsrep12479"],"URL":"https:\/\/doi.org\/10.1038\/srep12479","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,28]]},"assertion":[{"value":"24 March 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12479"}}